CITIC Securities says since early 2026 China's innovative-drug market has seen
rapid domestic volume growth. Interim results from leading innovators show fast
revenue expansion driven by new products and biopharma firms are moving into a
profitability inflection. Overseas programs are entering Phase
III/registration-study stages, and several upcoming international conferences
create concentrated data catalysts. The firm highlights three investor
priorities: (1) leading internationalized innovators poised for global value
realization; (2) top domestic innovators entering a new product-ramp growth
phase; (3) pipeline assets with global potential whose internationalization may
accelerate value realization. CITIC maintains an Outperform rating on the
sector.
